FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules on October 15, 2010. Launch preparations are complete and shipments will commence shortly. Dr. Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30 mg.

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes…

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

How Digital Dentistry Creates More Comfortable Patient Journeys

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Integrating high-voltage leak detection into automated visual inspection

Aligning Global Clinical Trials with Standardized Drug Data

Who are the Top Vendors for Budget-Friendly Laboratory Supplies?

Future-proof vial filling – How flexibility Along the Line Defines Success

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Syntegon and Lyocontract: Growing Together

Kindeva Appoints Mike Cowhig as Chief Legal Officer

Inizio Ignite Builds its Connected Solution with Key Leadership Appointments

QIAGEN’s QuantiFERON-TB Gold Plus shows cost-effectiveness compared with TST

Inizio Evoke Appoints Kristin Ryan as EVP to Lead AI Healthcare…

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

Integrating high-voltage leak detection into automated...

The Invisible Costs Undermining Pharma Profit...

SGD Pharma Advances Nasal Drug Delivery...

Structural Pricing Pressure is Reshaping Pharma...

Merck Targets $70B Revenue in 2026...

U.S. Drug Pricing Reset Becomes Real...

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

How Digital Dentistry Creates More Comfortable Patient Journeys

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Integrating high-voltage leak detection into automated visual inspection

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes...